Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04497688
Status:
UNKNOWN
Last Update Posted:
2020-08-04
First Post:
2020-07-27
Brief Title:
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkins Lymphoma
Sponsor:
CSPC Baike Shandong Biopharmaceutical Co Ltd
Organization:
CSPC Baike Shandong Biopharmaceutical Co Ltd
Study Overview
Official Title:
A Multi-center Open-label Single-arm Study to Evaluate the Efficacy and Safety of PEG-rhG-CSFJinyouli in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkins Lymphoma
Status:
UNKNOWN
Status Verified Date:
2020-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main treatments for non-Hodgkins lymphoma are surgery radiotherapy chemotherapy and bone marrow transplantation Neutropenia is the most common and serious complication of most chemotherapy This study is a multi-center open-label single-arm clinical study to evaluate the efficacy and safety of jinyouli in preventing neutropenia in patients with non Hodgkins lymphoma after chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None